These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15904772)
21. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta. Gökşen D; Coker M; Darcan S; Köse T; Kara S Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111 [TBL] [Abstract][Full Text] [Related]
22. Do bisphosphonates make children's bones better or brittle? Marini JC N Engl J Med; 2003 Jul; 349(5):423-6. PubMed ID: 12890840 [No Abstract] [Full Text] [Related]
23. Osteogenesis imperfecta, current and future medical treatment. Rauch F; Glorieux FH Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881 [TBL] [Abstract][Full Text] [Related]
24. [Treatment of osteogenesis imperfecta with sodium fluoride]. Lender M; Perelman A; Eilon G; Menczel J Harefuah; 1975 Jan; 88(2):53-5. PubMed ID: 1112549 [No Abstract] [Full Text] [Related]
25. Effects of vitamin C on osteogenesis imperfecta. Kurz D; Eyring EJ Pediatrics; 1974 Jul; 54(1):56-61. PubMed ID: 4834301 [No Abstract] [Full Text] [Related]
26. Letter to the Editor: Therapies for Osteogenesis Imperfecta. Sousa S; Godinho F; Santos MJ Acta Med Port; 2017 Feb; 30(2):156-157. PubMed ID: 28527487 [No Abstract] [Full Text] [Related]
27. Shin splints: an unexpected effect of bisphosphonates in osteogenesis imperfecta. Balink H Clin Nucl Med; 2009 Feb; 34(2):87-8. PubMed ID: 19352259 [No Abstract] [Full Text] [Related]
28. Neridronic acid for the treatment of bone metabolic diseases. Gatti D; Viapiana O; Idolazzi L; Fracassi E; Adami S Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1305-11. PubMed ID: 19761412 [TBL] [Abstract][Full Text] [Related]
29. Are drugs helpful in adults with osteogenesis imperfecta? Chevrel G; Meunier PJ Rev Rhum Engl Ed; 1997 May; 64(5):283-6. PubMed ID: 9190000 [No Abstract] [Full Text] [Related]
30. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment]. Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883 [TBL] [Abstract][Full Text] [Related]
31. Pyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta. Granda JL; Falvo KA; Bullough PG Clin Orthop Relat Res; 1977; (126):228-31. PubMed ID: 202425 [TBL] [Abstract][Full Text] [Related]
37. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. Lindsay R J Clin Invest; 2002 Nov; 110(9):1239-41. PubMed ID: 12417561 [No Abstract] [Full Text] [Related]
38. Alternative indications for bisphosphonate therapy. Landesberg R; Eisig S; Fennoy I; Siris E J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812 [TBL] [Abstract][Full Text] [Related]
39. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Land C; Rauch F; Travers R; Glorieux FH Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117 [TBL] [Abstract][Full Text] [Related]
40. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]